Last reviewed · How we verify
HIV Anti-retroviral Background Therapy
HIV Anti-retroviral Background Therapy is a CCR5 antagonist Small molecule drug developed by Theratechnologies. It is currently in Phase 2 development for HIV-1 infection.
Inhibits HIV replication by targeting the CCR5 receptor
Inhibits HIV replication by targeting the CCR5 receptor Used for HIV-1 infection.
At a glance
| Generic name | HIV Anti-retroviral Background Therapy |
|---|---|
| Sponsor | Theratechnologies |
| Drug class | CCR5 antagonist |
| Target | CCR5 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Theratechnologies' drug works by binding to the CCR5 receptor on the surface of host cells, preventing HIV from entering and replicating within those cells.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- The Visceral Adiposity Measurement and Observation Study
- Adding New Drugs for HIV Infected Patients Failing Current Therapy (PHASE1, PHASE2)
- Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs (PHASE2)
- Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r (PHASE4)
- T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents (PHASE2)
- SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC (PHASE3)
- Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure (PHASE4)
- Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIV Anti-retroviral Background Therapy CI brief — competitive landscape report
- HIV Anti-retroviral Background Therapy updates RSS · CI watch RSS
- Theratechnologies portfolio CI
Frequently asked questions about HIV Anti-retroviral Background Therapy
What is HIV Anti-retroviral Background Therapy?
How does HIV Anti-retroviral Background Therapy work?
What is HIV Anti-retroviral Background Therapy used for?
Who makes HIV Anti-retroviral Background Therapy?
What drug class is HIV Anti-retroviral Background Therapy in?
What development phase is HIV Anti-retroviral Background Therapy in?
What are the side effects of HIV Anti-retroviral Background Therapy?
What does HIV Anti-retroviral Background Therapy target?
Related
- Drug class: All CCR5 antagonist drugs
- Target: All drugs targeting CCR5
- Manufacturer: Theratechnologies — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection
- Compare: HIV Anti-retroviral Background Therapy vs similar drugs
- Pricing: HIV Anti-retroviral Background Therapy cost, discount & access